CIMP definition | First author (year) | Subgroup | Subgroup size | Analysis | Survival | HR (95Â % CI) | Comparison group | p value | Covariates adjusted for | |
---|---|---|---|---|---|---|---|---|---|---|
CIMP+/CIMP-H | CIMP-L | |||||||||
CRC patients | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
 D 1 | Lee (2008) [16] | All | 134 | U | OS | 1.59 (0.87–2.88) |  | CIMP− | 0.13 | No |
 D 2 | Sanchez (2009) [21] | All | 391 | M | OS | 1.56 (0.88–2.78)a |  | CIMP− | 0.13 | Age, sex, stage, location, MSIb |
 D 6 | Ward (2003) [37] | All | 609 | U | OS | 1.30 (0.70–2.20) |  | CIMP− | 0.37 | No |
 D 7 | Kakar (2012) [39] | All | 33 | U | OS | 1.19 (0.51–2.58) |  | CIMP− | 0.69 | No |
 D 14 | Li (2014) [34] | All | 282 | M | OS | 2.31 (1.02–5.24) |  | CIMP− | 0.04 | Age, stage, location, differentiation |
 D 2 | Samadder (2013) [30] | All | 563 | M | OS | 1.12 (0.81–1.55) | 0.86 (0.60–1.23) | CIMP-N | 0.60 | Age, stage, grade, locationc |
 D 3 | Kim (2009) [18] | All | 320 | U | OS | 1.81 (0.91–3.66) | 1.33 (0.78–2.27) | CIMP-N | 0.24 | No |
 D 4 | Kim (2009) [18] | All | 320 | U | OS | 2.46 (1.16–5.19) | 1.30 (0.76–2.22) | CIMP-N | 0.05 | No |
 D 14 | Li (2014) [34] | All | 282 | M | OS | 3.06 (1.19–7.89) | 0.95 (0.60–1.52) | CIMP-N | 0.02 | Age, stage, location, differentiation |
CRC patients by cancer stages | ||||||||||
 D 14 | Li (2014) [34] | I–III | 149 | M | OS | 0.52 (0.12–2.22) |  | CIMP− | 0.38 | Age, stage, location, differentiation |
 D 6 | Ward (2003) [37] | I–III | 476 | U | OS | 1.20 (0.60–2.80) |  | CIMP− | 0.60 | No |
 D 11 | Barault (2008) [14] | I–II, colon, MSS | 246 | M | OSd | 2.90 (1.53–5.49) | 1.85 (1.37–2.51) | CIMP-N | <0.01 | Age, stage, BRAF, KRAS |
 D 2 | Donada (2013) [40] | II, colon | 120 | M | OS | 0.60 |  | CIMP− | 0.30 | All variablese |
 D 14 | Li (2014) [34] | III–IV | 129 | M | OS | 1.75 (0.95–3.23) |  | CIMP− | 0.07 | Age, stage, location, differentiation |
CRC patients by location of CRC | ||||||||||
 D 3 | Bae (2013) [28] | Proximal | 165 | M | OS | 0.84 (0.42–1.69) |  | CIMP− | 0.62 | Stage, differentiationf |
 D 3 | Bae (2013) [28] | Distal | 327 | M | OS | 1.35 (0.47–3.90) |  | CIMP− | 0.58 | Stage, differentiationf |
 D 4 | Ogino (2009) [19] | Colon | 649 | M | OS | 0.78 (0.47–1.29) | 1.01 (0.77–1.33) | CIMP-N |  | Age, sex, stage, BRAF, KRAS, MSIg |
 D 2 | Donada (2013) [40] | Colon, II | 120 | M | OS | 0.60 |  | CIMP− | 0.30 | All variablese |
 D 1 | Samowitz (2005) [13] | Colon, MSS | 803 | M | OS | 0.88 (0.66–1.18) |  | CIMP− |  | Age, stage, location, BRAF |
 D 11 | Barault (2008) [14] | Colon, MSS, I–II | 246 | M | OSd | 2.90 (1.53–5.49) | 1.85 (1.37–2.51) | CIMP− | <0.01 | Age, stage, BRAF, KRAS |
 D 3 | Bae (2013) [28] | Rectal | 242 | M | OS | 4.13 (1.27–13.46) |  | CIMP− | 0.02 | Stage, differentiationf |
CRC patients by microsatellite instability | ||||||||||
 D 1 | Lee (2008) [16] | MSS | 115 | U | OS | 1.96 (1.06–3.61) |  | CIMP− | 0.03 | No |
 D 6 | Ward (2003) [37] | MSS | 547 | M | OS | 2.10 (1.10–4.00) |  | CIMP− | 0.02 | Stage, vascular space invasion |
 D 7 | Kakar (2008) [15] | MSS | 69 | M | OS | 0.86 (0.35–2.13) |  | CIMP− | 0.70 | Age, sex, stage, LOH, BRAF |
 D 6 | Ward (2003) [37] | MSS, I–III | 464 | M | OS | 2.40 (0.94–6.00) |  | CIMP− | 0.06 | Stage, vascular space invasion |
 D 1 | Samowitz (2005) [13] | MSS, colon | 803 | M | OS | 0.88 (0.66–1.18) |  | CIMP− |  | Age, stage, location, BRAF |
 D 11 | Barault (2008) [14] | MSS, colon, I–II | 246 | M | OSd | 2.90 (1.53–5.49) | 1.85 (1.37–2.51) | CIMP-N | <0.01 | Age, stage, BRAF, KRAS |
CRC patients by microsatellite instability | ||||||||||
 D 3 | Bae (2011) [23] | MSI | 169 | M | OS | 2.81 (1.08–7.27) |  | CIMP− | 0.03 | Age, stage, BRAF, differentiationh |
 D 3 | Rhee (2012) [26] | MSI | 207 | M | OS | 3.05 (1.07–8.73) |  | CIMP− | 0.04 | Age, stage, location, BRAF/KRASi |